Karen Reckamp Profile | Cedars-Sinai ...

Dr. Karen Reckamp, MD

Claim this profile

Torrance Memorial Physician Network - Cancer Care

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
8 reported clinical trials
13 drugs studied

Area of expertise

1

Lung Cancer

Karen Reckamp, MD has run 6 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
MET positive
2

Non-Small Cell Lung Cancer

Karen Reckamp, MD has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
EGFR positive
MET positive

Affiliated Hospitals

Image of trial facility.

Cedars-Sinai Medical Center

Image of trial facility.

Torrance Memorial Physician Network / Cancer Care

Clinical Trials Karen Reckamp, MD is currently running

Image of trial facility.

Osimertinib + Carotuximab

for Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Recruiting

2 awards

Phase 1

15 criteria

Image of trial facility.

Bevacizumab + Chemoimmunotherapy + Atezolizumab

for Small Cell Lung Cancer

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.

Recruiting

1 award

Phase 2

11 criteria

More about Karen Reckamp, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Karen Reckamp, MD has experience with

  • Pembrolizumab
  • Ramucirumab
  • Carotuximab
  • Osimertinib
  • Chemotherapy
  • Seribantumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Karen Reckamp, MD specialize in?

Is Karen Reckamp, MD currently recruiting for clinical trials?

Are there any treatments that Karen Reckamp, MD has studied deeply?

What is the best way to schedule an appointment with Karen Reckamp, MD?

What is the office address of Karen Reckamp, MD?

Is there any support for travel costs?